рус / eng / kaz    
     

QazCovid-in

20.12.2020

Research Institute (RI) for Biological Safety Problems of the Ministry of Education and Science of the Republic of Kazakhstan held phase I and II of clinical trials of the locally produced vaccine QazCovid-in. Preliminary results of studies demonstrate high safety, potency and efficacy of the vaccine at 96%.

Askar Mamin visited RI located in the Korday district of Zhambyl region. According to the press service of the Prime Minister, the start of the final phase III of clinical trials on three thousand volunteers has been approved.

To date, the first volunteers have been vaccinated with the domestic vaccine in clinics in Almaty and Taraz. By the end of December this year, the vaccination of three thousand volunteers will be completed. The necessary batch of vaccine in the amount of 10 thous. doses will be produced for phase III.

"Mass vaccination with the domestic vaccine will begin in March 2021. First of all, medical workers, teachers, as well as representatives of risk groups with chronic diseases will be vaccinated on a voluntary basis," Mamin said.

The Prime Minister got acquainted with the construction of a Biopharmaceutical Vaccine Plant. Construction works are carried out according to the schedule. The plant is scheduled to be commissioned in March 2021. The production capacity will be 60 mln. doses per year. The Head of Government stressed the importance of further development and modernization of material and technical base of the Research Institute for Biological Safety Problems of the Ministry of Education and Science of the Republic of Kazakhstan to ensure domestic production of immunobiological drugs, including vaccines against coronavirus infection.

The Prime Minister visited the construction site of three houses with 180 apartments for RI research workers. The first house with 60 apartments will be commissioned in January 2021.

 


Views: 338
Saved: 23.07.2021





©2020 Барлық құқықтар сақталған.




Wait please...

Хорошая погода, не так ли?

Subscribe to the newsletter


The operation completed successfully.



ERROR!